Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trialFrancesco Perrone, Ciro Gallo, Michelino De Laurentiis et al.|European Journal of Cancer|2019Cited by 71
Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trialFrancesco Perrone, A. De Matteis, Francesco Nuzzo et al.|Annals of Oncology|2014Cited by 68
Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trialErmelinda De Maio, A. De Matteis, Carmen Pacilio et al.|BMC Cancer|2007Cited by 26
Biological characterization and selection criteria of adjuvant chemotherapy for early breast cancer: experience from the Italian observational NEMESI studyMatteo Clavarezza, Marco Venturini, Giorgio Mustacchi et al.|BMC Cancer|2012Cited by 8
Evaluation of TAG-72 as a serum marker in ovarian and breast carcinoma.Gennaro Esposito, Marco Salvatore, N. Panza et al.|PubMed|1991Cited by 3